Cutting edge: Retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation

Endocrinology

Volumn 154, Issue 9, 2013, Pages 3008-3015

  Moshkelgosha, Sajad ^a   So, Po Wah ^a   Deasy, Neil ^a   Diaz Cano, Salvador ^b   Banga, J Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; PLASMID DNA; RECEPTOR ANTIBODY; SOMATOMEDIN C RECEPTOR ANTIBODY; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; UNCLASSIFIED DRUG;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CD3+ T LYMPHOCYTE; CHEMOSIS; CONTROLLED STUDY; DNA MODIFICATION; ELECTROPORATION; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EXPERIMENTAL MODEL; EXTRAOCULAR MUSCLE; FEMALE; HISTOPATHOLOGY; HYPOTHYROIDISM; IMMUNIZATION; IN VIVO GENE TRANSFER; INFLAMMATION; INFLAMMATORY INFILTRATE; MACROPHAGE; MAST CELL; MOUSE; MUSCLE CELL; MYOFIBROSIS; MYOSITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; PRIORITY JOURNAL; THYROID FUNCTION; VASCULAR DISEASE; VASODILATATION;

ADIPOGENESIS; ADIPOSITY; ANIMALS; DISEASE MODELS, ANIMAL; ELECTROPORATION; EXOPHTHALMOS; EYE; FEMALE; GLYCOSAMINOGLYCANS; GRAVES OPHTHALMOPATHY; HUMANS; HYPEREMIA; HYPOTHYROIDISM; IMMUNOGLOBULINS, THYROID-STIMULATING; MICE; MICE, INBRED BALB C; OCULOMOTOR MUSCLES; OPTIC NEURITIS; ORBIT; PROTEIN SUBUNITS; RECEPTORS, THYROTROPIN; TRANSFECTION;

EID: 84883187837     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1576     Document Type: Article

References (30)

1. Weetman AP. Graves' disease. New Engl J Med. 2000;343:1236-1248.
2. Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves' disease. Immunol Res. 2012;54:191-203.
3. Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362:726-738.
4. Dickinson AJ. 2010 Clinical manifestation. In: WiersingaWM,Kahaly GJ, eds. Graves' Orbitopathy : A Multidisciplinary Approach-Questions And Answers. 2nd rev. ed. Basel, Switzerland: S. Karger; 2010;1-25.
5. Iyer S, Bahn R. Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab.. 2012;26:281-289.
6. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 1993;16:251-257.
7. Daǧdelen Su, Kong Y-C, Banga JP. Toward better models of hyperthyroid Graves' disease. Endocrinol Metab Clin North Am. 2009;38:343-354.
8. Wiesweg B, Johnson KT, Eckstein AK, Berchner-Pfannschmidt U. Current insights into animal models of Graves' disease and orbitopathy. Horm Metab Res. 2013;45:549-555.
9. Many MC, Costagliola S, Detrait M, Denef F, Vassart G, Ludgate MC. Development of an animal model of autoimmune thyroid eye disease. J Immunol. 1999;162:4966-4974.
10. Baker G, Mazziotti G, von Ruhland C, Ludgate M. Reevaluating thyrotropin receptor-induced mouse models of graves' disease and ophthalmopathy. Endocrinology. 2005;146:835-844.
11. Johnson KT, Wiesweg B, Schott M, et al. Examination of orbital tissues in murine models of Graves' disease reveals expression of UCP-1 and the TSHR in retrobulbar adipose tissues. Horm Metab Res. 2013;45:401-407.
12. Rao PV, Watson PF, Weetman AP, Carayanniotis G, Banga JP. Contrasting activities of thyrotropin receptor antibodies in experimental models of Graves' disease induced by injection of transfected fibroblasts or deoxyribonucleic acid vaccination. Endocrinology. 2003;144:260-266.
13. Gilbert JA, Gianoukakis AG, Salehi S, et al. Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves' disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways. J Immunol. 2006;176:5084-5092.
14. Kaneda T, Honda A, Hakozaki A, Fuse T, Muto A, Yoshida T. An improved Graves' disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice. Endocrinology. 2007;148:2335-2344.
15. Zhao SX, Tsui S, Cheung A, Douglas RS, Smith TJ, Banga JP. Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol. 2011;210:369-377.
16. Smith RS. Systematic Evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods. Boca Raton, LA; London, UK: CRC Press; 2002
17. Yin KC, Chen D, Bakhtiar R, Verch T. Evaluation of two ELISA methods to detect therapeutic anti-IGF1R antibodies in clinical study samples of dalotuzumab. Bioanalysis. 2011;3:2107-2117.
18. Boschi A, Daumerie Ch, SpiritusM,et al. Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy. Br J Ophthalmol. 2005;89:724-729.
19. Nagayama Y, Kita-Furuyama M, Ando T, Nakao K, Mizuguchi H, Hayakawa T, Eguchi K, Niwa M. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol. 2002;168:2789-2794.
20. Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest. 2003;111:1897-1904.
21. Cemazar M, Golzio M, Sersa G, Rols MP, Teissie J. Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand? Curr Pharm Des. 2006;12:3817-3825.
22. Chen CR, Pichurin P, Chazenbalk GD, et al. Low-dose immunization with adenovirus expressing the thyroid-stimulating hormone receptor A-subunit deviates the antibody response toward that of autoantibodies in human Graves' disease. Endocrinology. 2004;145:228-233.
23. McLachlan SM, Aliesky HA, Chen CR, Rapoport B. Role of self-tolerance and chronic stimulation in the long-term persistence of adenovirus-induced thyrotropin receptor antibodies in wild-type and transgenic mice. Thyroid. 2012; 22:931-937.
24. Nakahara M, Johnson K, Eckstein A, et al. Adoptive transfer of antithyrotropin receptor (TSHR) autoimmunity from TSHR knockout mice to athymic nude mice. Endocrinology. 2012;153:2034-2042.
25. McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid- stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid. 2013;23:14-24.
26. Wiersinga WM. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab. 2011;96:2386-2394.
27. Müller-ForellW,Kahaly GJ. Neuroimaging of Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:259-271.
28. Grubeck-Loebenstein B, Trieb K, Sztankay A, Holter W, Anderl H, Wick G. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest. 1994;93: 2738-2743.
29. van Zeijl CJ, van Koppen CJ, Surovtseva OV, et al. Complete inhibition of rhTSH-, Graves' Disease IgG-, and M22-Induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist. J Clin Endocrinol Metab. 2012;97:E781-E785.
30. Turcu AF, Kumar S, Neumann S, et al. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of graves ophthalmopathy. J Clin Endocrinol Metab. 2013; 98:2153-2159.